Breaking the Bottleneck of Cysteine Selective Modification: Triazine-Pyridine Chemistry Enables Precision Protein Coupling
Today we share significant research findings published in Science Advancesby a Chinese scientific team. The study reports a novel cysteine (Cys)-selective bioconjugation technology based on a modular 1,3,5-triazine scaffold—Triazine-Pyridinium Chemistry (TPC). This work addresses the critical need for Cys-selective reagents with higher stability in therapeutic applications such as antibody-drug conjugates (ADCs). Through systematic structural modifications and computational studies, the team optimized a reagent capable of achieving near-quantitative labeling of Cys (>95% yield) under physiological conditions (pH 7.4), while effectively suppressing reactivity towards tyrosine (Tyr), overcoming the limitations of early TPC probes. The study demonstrated its good compatibility with various peptides and proteins, including the therapeutic antibody trastuzumab, and showcased its potential in constructing ADCs. The optimized labeling method ensures excellent stability of the conjugates in biological environments, highlighting the practical application value of this approach.
Fig. 1. Modular 1,3,5-triazine chemistry.
01 Research Background
Cysteine is an ideal target for site-specific protein labeling due to the high nucleophilicity of its thiol group and its relatively low abundance on accessible protein surfaces. Although various Cys-selective bioconjugation technologies (such as thiol-maleimide click reactions, S-alkylation, S-arylation, etc.) have been developed and applied in ADC synthesis, developing new methods that combine high selectivity, high efficiency, and excellent stability remains a significant challenge. The authors' research group discovered in 2022 that probes based on Triazine-Pyridinium Chemistry (TPC), like probe 2, could label both tyrosine and cysteine under neutral, catalyst-free conditions but could not differentiate between them. Leveraging the highly modular nature of TPC chemistry, this study proposed the scientific hypothesis that precise modulation of substituents on the triazine ring and the pyridinium leaving group could suppress reactivity towards Tyr, thereby achieving absolute Cys selectivity. This work aims to evolve TPC from a dual-reactive platform into a specific, powerful tool for Cys labeling.
02 Innovative Highlights
- Breakthrough from "Dual Selectivity" to "Absolute Cys Selectivity" via Modular Design:
Utilizing the tunability of the 1,3,5-triazine scaffold, the research team synthesized a large library of TPC derivatives (e.g., 4a-j, 9a-r). Through systematic screening, they discovered that replacing the para-substituted pyridinium leaving group with an N,N-dimethylamino group (as in reagents 4f-j) completely suppressed Tyr labeling while retaining high reactivity towards Cys. This marks a key advancement in the precise control of TPC reactivity.
- Guiding Rational Design by Combining Computational Chemistry to Reveal Structure-Activity Relationships:
By calculating the bond dissociation energy (BDE) of the key C–N bond, the study found that reagents with good Cys selectivity (e.g., 4f-j) had significantly higher BDE values (99.47–105.97 kcal/mol) compared to non-selective reagents (<90 kcal/mol), establishing a correlation between BDE and selectivity to guide future computational predictions. Furthermore, DFT calculations indicated that the optimal reagent 9b had a low energy barrier (ΔG≠=6.6 kcal/mol) for the reaction with the Cys thiol, theoretically explaining its high efficiency.
Fig.2. Effect of leaving group on the Cys/Tyr selectivity of TPC reagents.
- Establishing a Stable, Efficient Labeling System Suitable for Physiological Environments:
Systematic optimization of the reaction conditions for the optimal reagent 9b determined that the best labeling results (>95% yield) were achieved in PBS buffer (pH 7.4). These conditions are highly compatible with physiological environments, and the reagent itself showed good stability under these conditions, highlighting its potential for direct application in biological systems.
- Successful Application to Site-Specific Modification of Therapeutic Antibodies and Validation of Therapeutic Potential:
The TPC reagent 9b was applied to the Cys-selective modification of the ADC model drug trastuzumab. By reducing interchain disulfide bonds and performing labeling with 9b, ADCs with a high drug-to-antibody ratio (DAR, average 5-6 sites labeled per antibody) were successfully constructed. Crucially, ELISA experiments demonstrated that the modified antibodies retained high affinity for the target HER2, indicating that TPC labeling did not disrupt the antibody's conformation and function, laying the foundation for its ADC application.
03 Results and Discussion
The study, through comprehensive experimental data, progressively validated the superior performance of the TPC reagent 9b.
3.1 Structural Optimization and Selectivity Verification
The team first screened the impact of the pyridinium leaving group. The initial reagent 4a efficiently labeled both a Cys-containing peptide (5, 95%) and a Tyr-containing peptide (6, 85%). By introducing electron-donating groups (particularly the paraN,N-dimethylamino group, as in 4f-j), absolute selectivity for Cys was successfully achieved (Cys labeling yield >99%, Tyr labeling completely suppressed). Subsequently, while keeping the optimal leaving group fixed, the team systematically varied the 6-position substituent on the triazine ring (9a-r), finding that the ethoxy-substituted 9b exhibited the best Cys labeling efficiency (97%).
3.2 Labeling Condition Optimization and Stability Assessment
9b showed high labeling efficiency (>95%) and good self-stability in PBS buffer at pH 7-10 but decomposed rapidly under strong acid or base conditions. Competition experiments further confirmed the absolute selectivity of 9b for Cys; it reacted specifically with Cys even in the presence of other nucleophilic amino acids (e.g., lysine, histidine). Additionally, increasing the equivalent of 9b accelerated the reaction, typically completing within 30 minutes using 3 equivalents (Fig. 3).
Fig. 3. Optimization of the Cys-selective modification conditions of compound 9b.
3.3 Substrate Generality and Conjugate Stability
The study applied 9b to label a series of model peptides (12a-20a) of varying lengths and sequences, all yielding high yields (84–98%), demonstrating its broad substrate adaptability. Particularly importantly, stability tests showed that the TPC conjugate (13b) was far more stable in human plasma than the traditional maleimide conjugate (13c). After 48 hours, the latter hydrolyzed by about 50%, while the former hydrolyzed by only ~15%, addressing the core drawback of the instability of maleimide-based ADCs in vivo(Fig. 4).
Fig. 4. Cys-selective modification of peptides using compound 9b and the stability of labeled products.
3.4 Application in Therapeutic Antibody Modification
Finally, the study demonstrated a practical application on trastuzumab (Fig. 5). Western blot, SDS-PAGE, and mass spectrometry analyses all confirmed that 9b could efficiently and selectively label the Cys thiols generated by TCEP reduction on the antibody. LC-MS/MS analysis identified specific labeling sites (e.g., heavy chain Cys²²⁹ and Cys²³²). The ELISA experiment provided key evidence, showing that even at high labeling levels, the antigen-binding capacity of the modified antibody was comparable to that of the unmodified antibody, fully demonstrating the biocompatibility and application safety of the TPC method.
Fig. 5. Selective interchain Cys labeling of trastuzumab.
04 Conclusion and Future Perspectives
This study successfully developed a novel, efficient, and highly selective cysteine bioconjugation method—Triazine-Pyridinium Chemistry (TPC). Through rational design and systematic optimization, the star reagent 9b was obtained, enabling rapid, near-quantitative labeling of Cys under physiological conditions while completely avoiding side reactions with Tyr. This method not only exhibits broad substrate adaptability but also produces triazine-based conjugates that demonstrate far superior plasma stability compared to traditional maleimide methods. Ultimately, the successful application on the therapeutic antibody trastuzumab signifies that TPC technology possesses immense potential for constructing stable, chemically homogeneous antibody-drug conjugates (ADCs). In the future, this technology platform can be further extended to the modification of other complex biomacromolecules, such as cyclic peptides and glycoproteins, and can be explored in combination with automated synthesis and high-throughput screening to accelerate the discovery of novel bioconjugate drugs. In summary, this work not only reports a practical bioconjugation tool but also showcases the powerful capability of modular synthetic chemistry in addressing key biomedical challenges.
Orginal Article:
Wang C, Yin R, Jiang H, Ma Q, Zhang H, Zheng S, Yu R, Liu H, Li X, Jiang T. Achieving cysteine-selective peptide/protein bioconjugation via tunable triazine-pyridine chemistry. Sci Adv. 2025 Dec 5;11(49):eaea6904.